Activity of trametinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory RAS pathway-mutated hematologic malignancies.

IF 3 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2024-10-19 DOI:10.1007/s00277-024-06046-7

Zhihui Li, Keyan Yang, Teng Xu, Lei Wang, Xianxuan Wang, Xiaopei Wen, Caiyan Zhang, Jingjing Wang, Xiaoyu Zheng, Tong Wu, Qinlong Zheng

引用次数: 0

查看原文本刊更多论文

曲美替尼作为异基因造血干细胞移植后的维持疗法，对复发或难治的RAS通路突变血液恶性肿瘤患者的活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.